Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMEV-Applied Molecular Evolution -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (69)	1/7/2003 11:35:01 AM
From: tuck	Respond to of 164

AMEV takes a small loss in this legal round: >>SAN DIEGO--(BUSINESS WIRE)--Jan. 6, 2003--Applied Molecular Evolution (AME) (Nasdaq: AMEV - News) today received a report and recommendation from the magistrate judge to the district judge in its legal action against MorphoSys AG and its wholly owned subsidiary MorphoSys USA, Inc. that MorphoSys' motion for summary judgment of non-infringement be allowed and that AME's motion for partial summary judgment of infringement be denied and all other motions be dismissed as moot. "AME filed a complaint asserting that MorphoSys is infringing the Kauffman patents. If the district judge adopts the recommendation of the magistrate judge that MorphoSys is not infringing the Kauffman patents, this will not affect AME's freedom to operate in its corporate collaborations or internal development program, including the recently announced product candidates AME-527 and AME-133," stated William D. Huse, M.D., Ph.D., President, CEO and Chairman of AME. "Additionally, the magistrate judge's recommendation does not affect the validity of the Kauffman patents." On June 25, 2001, AME filed a complaint against MorphoSys AG and its wholly owned subsidiary MorphoSys USA, Inc., in the United States District Court for the District of Massachusetts seeking injunctive relief and damages on behalf of the Company. The complaint alleges that MorphoSys AG and MorphoSys USA, Inc., are willfully infringing the Kauffman patent family under which AME holds an exclusive license.<< snip Cheers, Tuck